Research Analysts Issue Forecasts for IDYA Q2 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Equities research analysts at Wedbush issued their Q2 2025 earnings per share estimates for IDEAYA Biosciences in a research note issued on Tuesday, May 6th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.88) for the quarter. The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences' Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($3.69) EPS, FY2026 earnings at ($4.08) EPS, FY2027 earnings at ($3.82) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at $0.53 EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the business earned ($0.53) EPS.

A number of other research analysts have also weighed in on IDYA. Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Finally, Stephens reaffirmed an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.58.

IDEAYA Biosciences Price Performance

IDYA traded down $0.90 on Friday, reaching $17.45. 862,899 shares of the company's stock were exchanged, compared to its average volume of 991,391. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $44.42. The stock has a market cap of $1.53 billion, a PE ratio of -5.29 and a beta of 0.26. The stock's fifty day moving average price is $17.72 and its 200-day moving average price is $22.51.

Hedge Funds Weigh In On IDEAYA Biosciences

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd purchased a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at $35,000. CWM LLC raised its stake in IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after purchasing an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after purchasing an additional 1,546 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of IDEAYA Biosciences during the 4th quarter worth about $47,000. Finally, Signaturefd LLC grew its holdings in shares of IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after buying an additional 2,271 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.